Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis
- PMID: 28958829
- DOI: 10.1016/j.eururo.2017.09.011
Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis
Abstract
Of the patients undergoing radical cystectomy, 20-80% experience relapse. Minimally invasive methods for early detection of metastatic relapse after cystectomy and for monitoring ongoing therapy are urgently needed to improve individualised follow-up and treatment. Therefore, we evaluated the use of circulating tumour DNA (ctDNA) in plasma and urine to detect metastatic relapse after cystectomy and measure treatment efficacy. We exome sequenced tumour and germline DNA from patients with muscle-invasive bladder cancer and monitored ctDNA in 370 liquid biopsies throughout the disease courses by 84 personalised digital droplet polymerase chain reaction assays targeting 61 genes. Patients were prospectively recruited between 2013 and 2017. Patients with metastatic relapse had significantly higher ctDNA levels compared with disease-free patients (p<0.001). The median positive lead time between ctDNA detection in plasma and diagnosis of relapse was 101 d after cystectomy (range 0-932 d). Early detection of metastatic relapse and treatment response using liquid biopsies represents a novel, highly sensitive tool for monitoring patients, supporting clinicians, and guiding treatment decisions.
Patient summary: Measurement of tumour-specific mutations in plasma and urine may be a powerful tool to monitor response during treatment and identify early signs of metastatic disease.
Keywords: Biomarker; Cell-free DNA; Droplet digital polymerase chain reaction; Liquid biopsy; Minimally invasive monitoring; Neoadjuvant chemotherapy; Personalised analysis; Plasma; Reservoir urine; Treatment response.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.Eur Urol. 2018 Apr;73(4):541-542. doi: 10.1016/j.eururo.2017.10.011. Epub 2017 Oct 31. Eur Urol. 2018. PMID: 29097099 No abstract available.
-
Detection of circulating tumor DNA for advanced bladder cancer: where are we going?Transl Androl Urol. 2018 Mar;7(Suppl 1):S101-S103. doi: 10.21037/tau.2018.01.01. Transl Androl Urol. 2018. PMID: 29644172 Free PMC article. No abstract available.
-
Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.J Urol. 2019 Nov;202(5):866. doi: 10.1097/01.JU.0000579460.83699.53. Epub 2019 Oct 9. J Urol. 2019. PMID: 31364936 No abstract available.
Similar articles
-
Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.Eur Urol. 2016 Jul;70(1):75-82. doi: 10.1016/j.eururo.2016.01.007. Epub 2016 Jan 20. Eur Urol. 2016. PMID: 26803478
-
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.Eur Urol. 2017 Jun;71(6):961-969. doi: 10.1016/j.eururo.2016.12.016. Epub 2017 Jan 6. Eur Urol. 2017. PMID: 28069289
-
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6. J Clin Oncol. 2019. PMID: 31059311
-
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11. Cancer Lett. 2020. PMID: 31610267 Review.
-
Recent progress with next-generation biomarkers in muscle-invasive bladder cancer.Int J Urol. 2017 Jan;24(1):7-15. doi: 10.1111/iju.13193. Epub 2016 Sep 6. Int J Urol. 2017. PMID: 27597124 Review.
Cited by
-
High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions.Oncologist. 2024 Sep 6;29(9):731-737. doi: 10.1093/oncolo/oyae198. Oncologist. 2024. PMID: 39096189 Free PMC article. Review.
-
The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Transl Cancer Res. 2020 Oct;9(10):6609-6623. doi: 10.21037/tcr-20-1243. Transl Cancer Res. 2020. PMID: 35117271 Free PMC article. Review.
-
Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer.Cancer Sci. 2019 Oct;110(10):3235-3243. doi: 10.1111/cas.14155. Epub 2019 Aug 10. Cancer Sci. 2019. PMID: 31368627 Free PMC article.
-
Immune status for monitoring and treatment of bladder cancer.Front Immunol. 2022 Sep 8;13:963877. doi: 10.3389/fimmu.2022.963877. eCollection 2022. Front Immunol. 2022. PMID: 36159866 Free PMC article. Review.
-
Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review.Cancers (Basel). 2021 Mar 22;13(6):1448. doi: 10.3390/cancers13061448. Cancers (Basel). 2021. PMID: 33810039 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous